Mackenzie Financial Corp lowered its position in Humana Inc (NYSE:HUM) by 12.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 5,805 shares of the insurance provider’s stock after selling 837 shares during the period. Mackenzie Financial Corp’s holdings in Humana were worth $1,440,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Fieldpoint Private Securities LLC purchased a new stake in shares of Humana during the third quarter valued at approximately $115,000. American Beacon Advisors Inc. purchased a new stake in shares of Humana during the fourth quarter valued at approximately $122,000. ClariVest Asset Management LLC purchased a new stake in shares of Humana during the third quarter valued at approximately $144,000. YorkBridge Wealth Partners LLC boosted its stake in shares of Humana by 99.0% during the fourth quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock valued at $159,000 after purchasing an additional 297 shares during the period. Finally, Daiwa SB Investments Ltd. boosted its stake in shares of Humana by 44.9% during the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after purchasing an additional 220 shares during the period. 96.84% of the stock is owned by institutional investors and hedge funds.
Shares of Humana Inc (HUM) opened at $272.50 on Friday. Humana Inc has a 52 week low of $203.48 and a 52 week high of $293.35. The company has a market capitalization of $37,518.89, a price-to-earnings ratio of 23.31, a P/E/G ratio of 1.48 and a beta of 0.95. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.48.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be paid a $0.50 dividend. This is a positive change from Humana’s previous quarterly dividend of $0.40. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 dividend on an annualized basis and a yield of 0.73%. Humana’s dividend payout ratio (DPR) is presently 9.59%.
Humana declared that its board has initiated a share repurchase program on Thursday, December 14th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the insurance provider to reacquire shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.
HUM has been the subject of a number of analyst reports. Zacks Investment Research lowered Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 19th. Cowen reissued a “buy” rating and set a $285.00 price objective on shares of Humana in a research note on Wednesday, December 13th. Cantor Fitzgerald reissued a “hold” rating and set a $230.00 price objective on shares of Humana in a research note on Tuesday, December 5th. Jefferies Group raised Humana from a “hold” rating to a “buy” rating and set a $221.00 price objective for the company in a research note on Friday, January 12th. Finally, Oppenheimer increased their price objective on Humana from $275.00 to $305.00 and gave the company an “outperform” rating in a research note on Thursday, February 8th. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $270.47.
In other Humana news, CEO Bruce D. Broussard sold 14,075 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $274.32, for a total value of $3,861,054.00. Following the completion of the transaction, the chief executive officer now owns 113,896 shares in the company, valued at $31,243,950.72. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Brian P. Leclaire sold 1,679 shares of the stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $245.97, for a total value of $412,983.63. Following the completion of the transaction, the senior vice president now owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The disclosure for this sale can be found here. Insiders sold 40,579 shares of company stock valued at $10,842,942 in the last ninety days. 0.80% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: This piece was posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3255315/mackenzie-financial-corp-cuts-holdings-in-humana-inc-hum.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.